OnKure Elects Directors at Annual Stockholder Meeting

OnKure Therapeutics ( (OKUR) ) just unveiled an announcement.

On May 27, 2025, OnKure Therapeutics held its Annual Meeting of Stockholders where two key proposals were voted on. Drs. Isaac Manke and Nicholas Saccomano were elected as Class I directors, and KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (OKUR) stock is a Buy with a $33.00 price target. To see the full list of analyst forecasts on OnKure Therapeutics stock, see the OKUR Stock Forecast page.

Spark’s Take on OKUR Stock

According to Spark, TipRanks’ AI Analyst, OKUR is a Neutral.

OnKure Therapeutics is experiencing significant financial challenges with no revenue and persistent losses, impacting its financial performance score. The technical analysis indicates a bearish trend, compounded by a negative MACD and oversold RSI and Stochastic levels, suggesting caution. Valuation is weak due to a negative P/E ratio, highlighting the need for substantial operational improvements. Overall, the company’s stock presents high risk, requiring strategic shifts to enhance financial health and investor appeal.

To see Spark’s full report on OKUR stock, click here.

More about OnKure Therapeutics

OnKure Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for cancer treatment.

Average Trading Volume: 137,932

Technical Sentiment Signal: Sell

Current Market Cap: $30.53M

For a thorough assessment of OKUR stock, go to TipRanks’ Stock Analysis page.